Lucía Cañizares‐Moscato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucía Cañizares‐Moscato has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ernest Palomer
Molecular Neuropathology Unit, Physiological and Pathological Processes Program, Centro de Biologia Molecular Severo Ochoa (CBM), CSIC-UAM, Madrid, Spain
2 shared publications - Javier Isoler-Alcaraz
Molecular Neuropathology Unit, Physiological and Pathological Processes Program Centro de Biología Molecular Severo Ochoa, CSIC‐UAM Madrid Spain
2 shared publications - Jose Ruiz-Iglesias
Molecular Neuropathology Unit, Physiological and Pathological Processes Program Centro de Biología Molecular Severo Ochoa, CSIC‐UAM Madrid Spain
2 shared publications - Adrián de Rus-Moreno
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication - Aida Contreras-Pérez
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication - Alicia Gómez-Moya
Genome maintenance and instability Unit, Genome dynamics and function Program, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (5)
Beyond Bulk: Cell‐Type‐Resolved Epigenomics as the Path Forward in Alzheimer's Disease Research
Alzheimer's disease (AD) is a complex neurodegenerative disorder in which most risk variants are noncoding and are enriched at gene regulatory regions, implicating epigenetic mechanisms as central mediators of disease pathogenesis. For most of the history of AD epigenetics research, bulk tissue analysis has dominated, obscuring the fundamentally distinct epigenomic landscapes of individual brain cell types and masking cell‐type‐specific contributions to disease. Advances in single‐cell and single‐nucleus sequencing, fluorescence‐activated nuclei sorting and multiplexed epigenomic platforms have transformed this landscape, enabling cell‐type‐resolved profiling of chromatin accessibility, DNA methylation, histone modifications and transcription across the major neuronal, glial and neurovascular populations of the human brain. Here, we review these advances, structured around the argument that cell‐type resolution is not a methodological refinement but a conceptual necessity. We describe the distinct epigenomic programs disrupted in neurons, microglia, astrocytes, oligodendrocytes and neurovascular cells in AD, highlighting how each cell type responds to pathology. We discuss the discovery of epigenomic erosion, the progressive loss of cell‐type‐specific epigenomic identity across virtually all brain cell populations as AD advances, as a unifying disease mechanism linking chromatin dysregulation to cognitive decline. Finally, we identify critical gaps in current knowledge, including the near‐complete absence of cell‐type‐resolved histone modification and DNA methylation data for most brain cell types, the underrepresentation of rare populations in standard preparations and the untapped potential of metabolic acylation marks as indicators of the epigenome–metabolism interface in neurodegeneration.
- 9 September 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (5)
Open AccessBeyond Bulk: Cell‐Type‐Resolved Epigenomics as the Path Forward in Alzheimer's Disease Research
Alzheimer's disease (AD) is a complex neurodegenerative disorder in which most risk variants are noncoding and are enriched at gene regulatory regions, implicating epigenetic mechanisms as central mediators of disease pathogenesis. For most of the history of AD epigenetics research, bulk tissue analysis has dominated, obscuring the fundamentally distinct epigenomic landscapes of individual brain cell types and masking cell‐type‐specific contributions to disease. Advances in single‐cell and single‐nucleus sequencing, fluorescence‐activated nuclei sorting and multiplexed epigenomic platforms have transformed this landscape, enabling cell‐type‐resolved profiling of chromatin accessibility, DNA methylation, histone modifications and transcription across the major neuronal, glial and neurovascular populations of the human brain. Here, we review these advances, structured around the argument that cell‐type resolution is not a methodological refinement but a conceptual necessity. We describe the distinct epigenomic programs disrupted in neurons, microglia, astrocytes, oligodendrocytes and neurovascular cells in AD, highlighting how each cell type responds to pathology. We discuss the discovery of epigenomic erosion, the progressive loss of cell‐type‐specific epigenomic identity across virtually all brain cell populations as AD advances, as a unifying disease mechanism linking chromatin dysregulation to cognitive decline. Finally, we identify critical gaps in current knowledge, including the near‐complete absence of cell‐type‐resolved histone modification and DNA methylation data for most brain cell types, the underrepresentation of rare populations in standard preparations and the untapped potential of metabolic acylation marks as indicators of the epigenome–metabolism interface in neurodegeneration.
- Open Access
- 24 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77236
A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control
Living cell therapies lack robust, reversible mechanisms for externally controlling therapeutic activity after administration, limiting their safety and clinical adaptability. Here we engineer a drug‐gated cellular immunotherapy platform in which T cells function as programmable factories that secrete two inactive antibody modules whose extracellular assembly into a functional bispecific T cell engager (TCE) is controlled by a small‐molecule input. Using a rapalog‐inducible FKBP‐FRB* heterodimerization switch, we design a split CD19 × CD3 engager architecture that remains inactive in the absence of drug and assembles on demand upon rapalog exposure. A 2A‐peptide bicistronic construct enables coordinated expression and secretion of both modules, allowing precise drug‐dependent control of TCE formation in situ. Drug administration quantitatively regulates T cell activation and cytotoxicity against CD19 + targets in vitro, with stringent OFF‐state behavior in the absence of rapalog. In xenograft models, systemic rapalog administration induces on‐demand anti‐tumor activity without evidence of treatment‐related toxicity, demonstrating reversible pharmacological control of a locally secreted therapeutic interface. We further extend this strategy to an EGFR‐targeting TCE, demonstrating the modularity and broad adaptability of the platform across distinct antigen specificities. This work introduces a generalizable engineering framework for externally programmable cell therapies, enabling tunable, safety‐by‐design control of T cell‐based immunotherapies.
- 24 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77236
Open AccessA Drug‐Gated, Modular STAb‐T Immunotherapy With External Control
Living cell therapies lack robust, reversible mechanisms for externally controlling therapeutic activity after administration, limiting their safety and clinical adaptability. Here we engineer a drug‐gated cellular immunotherapy platform in which T cells function as programmable factories that secrete two inactive antibody modules whose extracellular assembly into a functional bispecific T cell engager (TCE) is controlled by a small‐molecule input. Using a rapalog‐inducible FKBP‐FRB* heterodimerization switch, we design a split CD19 × CD3 engager architecture that remains inactive in the absence of drug and assembles on demand upon rapalog exposure. A 2A‐peptide bicistronic construct enables coordinated expression and secretion of both modules, allowing precise drug‐dependent control of TCE formation in situ. Drug administration quantitatively regulates T cell activation and cytotoxicity against CD19 + targets in vitro, with stringent OFF‐state behavior in the absence of rapalog. In xenograft models, systemic rapalog administration induces on‐demand anti‐tumor activity without evidence of treatment‐related toxicity, demonstrating reversible pharmacological control of a locally secreted therapeutic interface. We further extend this strategy to an EGFR‐targeting TCE, demonstrating the modularity and broad adaptability of the platform across distinct antigen specificities. This work introduces a generalizable engineering framework for externally programmable cell therapies, enabling tunable, safety‐by‐design control of T cell‐based immunotherapies.
- Open Access
EpiFlow: multidimensional single-cell epigenetic profiling by spectral flow cytometry
The epigenetic landscape of individual cells determines their identity and function, yet current methods for profiling chromatin modifications at single-cell resolution remain low-throughput, costly, or limited in parametric depth. Here we present EpiFlow, a spectral flow cytometry-based platform that enables the simultaneous quantification of 16 epigenetic markers, including histone post-translational modifications, DNA methylation, and hydroxymethylation, at the single-cell level. We demonstrate that EpiFlow is robust across species from yeast to mammals and resolves biologically meaningful epigenetic transitions during the cell cycle, stem cell differentiation, germinal centre B cell maturation, diabetic liver remodelling, and seizure-induced chromatin reprogramming. High-dimensional integration of EpiFlow data enables cell-type classification based solely on epigenetic profiles in liver, brain, blood, and cancer. Furthermore, EpiFlow detects on-target and off-target/indirect effects of epigenetic drugs in a high-throughput-compatible format. Collectively, these results establish EpiFlow as a broadly applicable platform for single-cell epigenetic analysis in basic, pharmaceutical, and translational research.
Open AccessEpiFlow: multidimensional single-cell epigenetic profiling by spectral flow cytometry
The epigenetic landscape of individual cells determines their identity and function, yet current methods for profiling chromatin modifications at single-cell resolution remain low-throughput, costly, or limited in parametric depth. Here we present EpiFlow, a spectral flow cytometry-based platform that enables the simultaneous quantification of 16 epigenetic markers, including histone post-translational modifications, DNA methylation, and hydroxymethylation, at the single-cell level. We demonstrate that EpiFlow is robust across species from yeast to mammals and resolves biologically meaningful epigenetic transitions during the cell cycle, stem cell differentiation, germinal centre B cell maturation, diabetic liver remodelling, and seizure-induced chromatin reprogramming. High-dimensional integration of EpiFlow data enables cell-type classification based solely on epigenetic profiles in liver, brain, blood, and cancer. Furthermore, EpiFlow detects on-target and off-target/indirect effects of epigenetic drugs in a high-throughput-compatible format. Collectively, these results establish EpiFlow as a broadly applicable platform for single-cell epigenetic analysis in basic, pharmaceutical, and translational research.